{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"The primary objective of this study is to determine the safety (MTD) of CD25/Treg-depleted donor lymphocyte infusion (DLI) plus Ipilimumab in patients with myeloid relapse after matched-HCT. Participants will be evaluated for dose limiting toxicities (DLTs) at day 43. DLTs explained within section 5.4 of the protocol.","groups":[{"description":"Ipilimumab: Ipilimumab is an antibody that acts against CTLA-4 -Ipilimumab is administered intravenously every 12 weeks\n\nCD25hi Treg depleted DLI: Donor lymphocyte product\n\n-Patients will receive a defined dose of CD25hi Treg depleted DLI intravenously","id":"OG000","title":"Ipilimumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 43 (6 weeks)","title":"Maximum Tolerated Dose (MTD) for Ipilimumab","type":"PRIMARY","unitOfMeasure":"mg/kg"}